Author:
Watanabe Sho,Shimoi Tatsunori,Nishikawa Tadaaki,Kawachi Asuka,Okuma Hitomi Sumiyoshi,Tokura Momoko,Yazaki Shu,Mizoguchi Chiharu,Arakaki Motoko,Saito Ayumi,Kita Shosuke,Yamamoto Kasumi,Kojima Yuki,Sudo Kazuki,Noguchi Emi,Yoshida Akihiko,Kawai Akira,Fujiwara Yasuhiro,Yonemori Kan
Abstract
AbstractPrognostic value of hematologic indices and their association with the tumor microenvironment (TME) remain unclear in advanced soft tissue sarcoma (STS). We aimed to evaluate their prognostic value and correlation with the TME status in advanced STS treated with first-line doxorubicin (DXR) therapy. Clinical data and three hematological indices, including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio, were collected from 149 patients with advanced STS. The TME status was pathologically examined by CD3, CD68, and CD20 staining of resected tumor slides. In a multivariate Cox analysis, low LMR and absence of primary tumor resection were independently associated with worse overall survival (OS) (HR 3.93,p = 0.001; HR 1.71,p = 0.03). A prognostic model using these variables predicted OS with greater area under curves than those obtained using Systemic Inflammatory Score and Glasgow Prognostic Score. The LMR significantly correlated with the tumoral CD3/CD68-positive cell ratio in surgical specimens (R = 0.959,p = 0.04). In conclusion, LMR was a prognostic factor in advanced STS treated with first-line DXR therapy. LMR could partially reflect anti-tumor immunity in the TME and have the prognostic value. The potential role of LMR as an indicator of TME status warrants further investigation.
Publisher
Springer Science and Business Media LLC
Reference86 articles.
1. Gamboa, A. C., Gronchi, A. & Cardona, K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J. Clin. 70, 200–229. https://doi.org/10.3322/caac.21605 (2020).
2. Cancer Research UK. Soft tissue sarcoma survival statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/soft-tissue-sarcoma/survival.
3. American Cancer Society. Survival rates for soft tissue sarcoma. https://www.cancer.org/cancer/soft-tissue-sarcoma/detection-diagnosis-staging/survival-rates.
4. National Comprehensive Cancer Network. Soft tissue sarcoma, version 22022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 20, 815–833. https://doi.org/10.6004/jnccn.2022.0035 (2022).
5. Gronchi, A. et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 1348–1365. https://doi.org/10.1016/j.annonc.2021.07.006 (2021).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献